Email ID
Password
Scrip   
Biovitrum completes CBT divestment
25 November 2009
Simon Varcoe

Biovitrum has completed the divestment of Cambridge Biotechnology (CBT) to Proximagen Neuroscience for a percentage of future revenues generated from CBT's pipeline.

CBT's clinical stage projects consist of 5-HT2C agonists and 5-HT6 antagonists and its preclinical stage projects include...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36